GLP-1 & Metabolic Health Programme

Specialist-prescribed GLP-1 receptor agonist therapy and metabolic health optimisation for patients with obesity, type 2 diabetes, or insulin resistance, supervised by a consultant endocrinologist.

Dr Daphne Lee's GLP-1 and metabolic health programme offers one of Singapore's most clinically credible pathways to GLP-1 receptor agonist therapy, prescribed and monitored by a consultant endocrinologist rather than a GP. GLP-1 receptor agonists — a class that includes semaglutide (Ozempic, Wegovy) and liraglutide (Saxenda, Victoza) — are the most effective pharmacological tools currently available for weight reduction in patients with obesity and metabolic dysfunction. They work by mimicking the incretin hormone GLP-1, suppressing appetite, slowing gastric emptying, and improving insulin sensitivity. As an endocrinologist, Dr Lee is uniquely positioned to select, initiate, and titrate GLP-1 agents within the context of a patient's full metabolic and hormonal picture — assessing cardiovascular risk, renal function, thyroid history (GLP-1 agonists are contraindicated in medullary thyroid carcinoma), and co-existing diabetes management before prescribing. The programme begins with a specialist assessment including blood panel, medical history review, and metabolic profiling. Where GLP-1 therapy is indicated, the appropriate agent and starting dose are selected, with structured titration and regular follow-up consultations to track weight loss, glycaemic markers, and tolerability. Patients with type 2 diabetes may have GLP-1 therapy integrated with their broader diabetes management protocol. This programme is suitable for patients with BMI ≥27 with comorbidities or BMI ≥30, and those with type 2 diabetes seeking optimised glycaemic control alongside weight reduction. Consultations are available at Mount Elizabeth Novena and Gleneagles Medical Centre.